Resmed (RSMDF) Gross Profit (2009 - 2026)

Resmed (RSMDF) has reported Gross Profit for 18 consecutive years, with $861.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Profit rose 5.02% year-over-year to $861.2 million; the trailing twelve-month figure through Jun 2026 stood at $3.5 billion (up 12.99% YoY), and the FY2026 full-year result was $3.5 billion, up 12.99% from the prior year.
• Gross Profit retreated to $861.2 million in Q2 2026 per RSMDF's latest filing, from $891.0 million in the prior quarter.
• Across five years, Gross Profit topped out at $891.0 million in Q1 2026 and bottomed at $491.2 million in Q1 2022.
• Historically, Gross Profit has averaged $696.2 million across 5 years, with a median of $704.2 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Gross Profit grew 25.76% in 2023, then grew 5.02% in 2026.
• Over 5 years, Gross Profit stood at $579.7 million in 2022, then increased by 11.6% to $646.9 million in 2023, then climbed by 16.13% to $751.3 million in 2024, then rose by 16.96% to $878.7 million in 2025, then decreased by 1.99% to $861.2 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $861.2 million, $891.0 million, and $878.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.